Education
About Us
Working with TipRanks
Follow Us
Spero Therapeutics (SPRO)
NASDAQ:SPRO
SPRO Stock Chart & Stats
$2.29
-$0.03(-2.91%)
At close: 4:00 PM EST
$2.29
-$0.03(-2.91%)
Day’s Range― - ―
52-Week Range$0.51 - $3.22
Previous CloseN/A
Volume61.58K
Average Volume (3M)241.30K
Market Cap
$129.02M
Enterprise Value$84.32M
Total Cash (Recent Filing)$48.62M
Total Debt (Recent Filing)$3.35M
Price to Earnings (P/E)―
Beta1.69
Next Earnings
Mar 26, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding56,339,294
10 Day Avg. Volume331,200
30 Day Avg. Volume241,300
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.21
Price to Sales (P/S)1.16
P/FCF Ratio-2.37
Enterprise Value/Market Cap0.65
Enterprise Value/Revenue2.36
Enterprise Value/Gross Profit-1.16
Enterprise Value/Ebitda-1.87
Forecast
1Y Price Target
$4.00Price Target Upside74.67% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-0.64
Revenue Forecast (FY)$800.00K
Bulls Say, Bears Say
Bulls Say
Clinical Trial OutcomeA Phase 3 tebipenem trial met its primary efficacy endpoint and will stop early for efficacy, strengthening the case for regulatory submission and potential accelerated market access.
Financial RunwayCurrent cash reserves combined with reduced research spending create an extended financial runway to support late-stage development and regulatory activities.
Partner Licensing And RoyaltiesThe GSK licensing agreement includes milestone payments and tiered royalties that could provide significant non-dilutive revenue if regulatory and commercial milestones are achieved.
Bears Say
Milestone Payment ShortfallA prorated milestone payment reduces expected near-term cash inflows from the GSK partnership, lowering previously anticipated non-dilutive funding tied to trial outcomes.
Ongoing Operating LossesA reported net loss highlights persistent operating deficits and increases the likelihood of needing additional financing, which could dilute existing shareholders.
Partner Dependency RiskHeavy reliance on milestone and royalty payments from a single collaboration concentrates financial outcomes on partner decisions and regulatory timing, increasing revenue uncertainty.
Spero Therapeutics News
SPRO FAQ
What was Spero Therapeutics’s price range in the past 12 months?
Spero Therapeutics lowest stock price was $0.51 and its highest was $3.22 in the past 12 months.
What is Spero Therapeutics’s market cap?
Spero Therapeutics’s market cap is $129.02M.
When is Spero Therapeutics’s upcoming earnings report date?
Spero Therapeutics’s upcoming earnings report date is Mar 26, 2026 which is in 47 days.
How were Spero Therapeutics’s earnings last quarter?
Spero Therapeutics released its earnings results on Nov 13, 2025. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.25 by $0.12.
Is Spero Therapeutics overvalued?
According to Wall Street analysts Spero Therapeutics’s price is currently Undervalued.
Does Spero Therapeutics pay dividends?
Spero Therapeutics pays a Quarterly dividend of $0.015 which represents an annual dividend yield of N/A. See more information on Spero Therapeutics dividends here
What is Spero Therapeutics’s EPS estimate?
Spero Therapeutics’s EPS estimate is -0.2.
How many shares outstanding does Spero Therapeutics have?
Spero Therapeutics has 56,339,294 shares outstanding.
What happened to Spero Therapeutics’s price movement after its last earnings report?
Spero Therapeutics reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.25. Following the earnings report the stock price went down -1.23%.
Which hedge fund is a major shareholder of Spero Therapeutics?
Currently, no hedge funds are holding shares in SPRO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Spero Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$4.00 (74.67% Upside)
$4.00 (74.67% Upside)
Blogger Sentiment
Bullish
SPRO Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 22.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $237.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.2%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
204.11%
12-Months-Change
Fundamentals
Return on Equity
-95.29%
Trailing 12-Months
Asset Growth
-59.92%
Trailing 12-Months
Company Description
Spero Therapeutics
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
SPRO Stock 12 Month Forecast
Average Price Target
$4.00
▲(74.67% Upside)
Technical Analysis
Milestone Pharmaceuticals
―
Korro Bio
―
Connect Biopharma Holdings
―
Tenaya Therapeutics
―
Contineum Therapeutics, Inc. Class A
―
Ownership Overview
8.15% Insiders
4.07% Mutual Funds
0.18% Other Institutional Investors
84.41% Public Companies and
Individual Investors